VJHemOnc is committed to improving our service to you

IMW 2019 | Waldenström’s Macroglobulinemia venetoclax therapy

VJHemOnc is committed to improving our service to you

Jorge Castillo

Jorge Castillo, MD Dana-Farber Cancer Institute, Boston, MA, provides an update on phase II trials of venetoclax therapy as a treatment for Waldenström’s Macroglobulinemia patients, alongside an overview of the disease biology. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter